Currently, there is no FDA-approved-RUNX1 targeted therapy; however, RUNX1 can act as a promising biomarker for predicting the outcome of various types of cancer, and the targeted therapies of RUNX1 in cancer have immediately piqued the interest of scientists worldwide. The gene discussed is RUNX1; the disease is cancer.